Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for t...
Q1 2026
May 12, 2026
FY 2025
Mar 10, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 13, 2025